Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.31 |
| ▸ | BAD | Q92934 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884 | 1.00 | TSHR (0.48) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL9421049 | 0.93 | TSHR (0.52) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL62945 | 0.93 | TSHR (0.52) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL177122 | 0.91 | TSHR (0.50) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL21267 | 0.85 | — | — | |
| SCHEMBL1374665 | 0.85 | — | — | |
| SCHEMBL2952083 | 0.83 | MAOA (0.44) | TSHRMAOAMAOBCYP2A6MAPT | |
| SCHEMBL3543729 | 0.76 | TSHR (0.32) | TSHR | |
| SCHEMBL42412 | 0.74 | MEN1 (0.36) | TSHR | |
| SCHEMBL1098772 | 0.73 | TSHR (0.50) | TSHRMAOAMAOBCYP2A6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140798-A1 | MENIN INHIBITORS AND USE THEREOF | 成都先导药物开发股份有限公司 | 2024-07-04 | — | — | WO | disclosed |
| WO-2024127343-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE 1 (ENPP-1) | SRAVATHI AI TECHNOLOGY PRIVATE LIMITED (IN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024120360-A1 | PARP7 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2024-06-13 | — | — | WO | disclosed |
| WO-2024119866-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2024-06-13 | — | — | WO | disclosed |
| US-20240182473-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-06-06 | — | — | US | disclosed |
| WO-2024109788-A1 | PARP7 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 成都先导药物开发股份有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4365182-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | Ascentawits Pharmaceuticals, Ltd. (CN) | 2024-05-08 | — | — | EP | disclosed |
| US-20240140970-A1 | A DEUTERATED COMPOUND, AND PREPARATION METHOD AND USE THEREOF | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| WO-2008154601-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008083238-A2 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX INC. (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1582520-A1 | NOVEL PARP INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
| EP-0466220-B1 | Carboxy containing monomers and polymers and latices prepared from same | JOHNSON & JOHNSON CLIN DIAG (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5278267-A | Water insoluble vinyl aromatic polymer | EASTMAN KODAK COMPANY (US) | 1994-01-11 | — | — | US | disclosed |
| US-5210289-A | Homo or coploymers for medical diagnosis | EASTMAN KODAK COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-5149737-A | Carboxy group extended from polymer surface allows easier attachment of biological substances | EASTMAN KODAK COMPANY (US) | 1992-09-22 | — | — | US | disclosed |
| EP-0466220-A2 | Carboxy containing monomers and polymers and latices prepared from same | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1992-01-15 | — | — | EP | disclosed |
| US-4190656-A | VIRICIDES, ANTITUMOR AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | TSHR 4765/4885MAOA 2725/4885MAOB 2568/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | TSHR 4870/4885MAOA 1305/4885MAOB 477/4885 |
| US-20240182473-A1 | COMPOUNDS USEFUL IN HIV THERAPY | CD4, CCR5, G6PD | TSHR 4863/4885MAOA 878/4885MAOB 510/4885 |
| US-20240140970-A1 | A DEUTERATED COMPOUND, AND PREPARATION METHOD AND USE THEREOF | DMPK, DEK, DOHH | TSHR 1384/4885MAOA 2824/4885MAOB 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.